You are here: Industry Insights > NICE

News List

Report finds NICE unaware of financial interests of patient groups pharmaceutical-technology
January 21, 2019
A report by the London School of Tropical Medicine (LSTM) found that patient organisations consulted by the UK’s National institute of Health and Care Excellence (NICE) to advise on appraisals of medicines and treatments....
NICE declines to endorse Novartis’ pricey migraine drug Aimovig pharmaceutical-technology
January 14, 2019
National Institute for Health and Care Excellence (NICE) in the UK has rejected Novartis’ migraine prevention drug Aimovig (erenumab) saying the drug is not a cost-effective use of the NHS resources.....
NICE rejects Novartis’ migraine prevention drug Aimovig pharmaphorum
January 10, 2019
Some migraine sufferers in the UK hoping to get access to Novartis’ new migraine prevention drug Aimovig are facing disappointment after NICE rejected it in draft guidance.
NICE broadens approval for AstraZeneca’s severe asthma drug pharmaphorum
January 07, 2019
AstraZeneca’s Fasenra (benralizumab) has seen its fortunes reverse after NICE approved the drug for severe eosinophilic asthma – broadening its recommendations for......
NICE recommends Lenvima for advanced liver cancer pharmatimes
December 24, 2018
The National Institute for Health and Care excellence (NICE) has recommended Eisai and MSD’s Lenvima (lenvatinib), a potentially life-extending treatment for advanced hepatocellular carcinoma (HCC) in adults
NICE publishes updated guidance with expanded recommendation for Oncotype DX pharmatimes
December 21, 2018
The National Institute for Health and Care Excellence (NICE) has announced the release of a second set of guidelines recommending three tests as options to help NHS clinicians decide whether
EU & NICE authorise MSD's Keytruda for stage III melanoma pharmatimes
December 20, 2018
MSD’s Keytruda has been given a green light for use within the EU as an adjuvant treatment for stage III melanoma, and has also been made available on the NHS.
NICE expands its recommendation for Oncotype Dx test pharmaceutical-technology
December 20, 2018
The UK’s pricing regulator the National Institutes of Health and Care Excellence (NICE) has expanded its guidance for Genomic Health’s Oncotype Dx Breast Recurrence Score to include early lymph node (LN)-negative breast cancer......
NICE rejects Alnylam and Akcea’s amyloidosis drugs pharmaphorum
December 14, 2018
NICE has rejected two pioneering drugs for the rare inherited condition, hereditary transthyretin-related amyloidosis (hATTR) in first draft guidance.
NICE reject two treatments for fatal, ultra-rare disease – hATTR pharmafile
December 14, 2018
The NHS’ cost effectiveness body NICE has rejected two treatments for the rare inherited condition, hereditary transthyretin-related amyliodsis (hATTR), over concerns as to whether the drugs showed long term benefits.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page